Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKRINOL vs SODIUM TETRADECYL SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.
Allergic rhinitis,Nasal congestion
Treatment of uncomplicated spider veins (telangiectasias) and reticular veins,Treatment of small varicose veins (off-label for larger varicose veins)
Adults: 100 mg orally twice daily.
1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
Approximately 2.5 hours (range 1.5–4 hours) in patients with normal renal function. Clinical context: prolonged in renal impairment, requiring dose adjustment.
Not available; components may be metabolized via hepatic CYP enzymes.
Not extensively metabolized; primarily eliminated unchanged by the kidneys.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Primarily renal; approximately 95% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
99.5% (primarily to albumin; also to α1-acid glycoprotein).
Approximately 50% bound to plasma proteins (albumin and globulins).
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
0.2–0.3 L/kg, indicating distribution primarily within extracellular fluid and plasma volume.
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
Intravenous: 100% (direct intravascular administration). Oral: negligible due to extensive degradation and poor absorption.
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
No dose adjustment required for renal impairment.
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
Use with caution in Child-Pugh class C; no specific dose adjustment defined.
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
0.1-0.3 m L of 1% solution per injection, repeated as needed; maximum 5 m L per session.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
No specific adjustment; use lowest effective dose due to potential increased sensitivity.
None
None.
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Anaphylactic shock and severe allergic reactions have been reported.,Intra-arterial injection can cause severe necrosis or ischemia.,Extravasation may cause pain and tissue necrosis.,Use caution in patients with underlying arterial disease or hypercoagulable states.,Thromboembolic events including deep vein thrombosis and pulmonary embolism have been reported.
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
Known hypersensitivity to sodium tetradecyl sulfate or any component of the formulation,Acute thromboembolic disease,Severe peripheral arterial disease,Valvular incompetence of the deep venous system,Uncontrolled systemic disease (e.g., diabetes, thyroid disorders),Local infection or inflammation at the injection site
No known food interactions with topical naftifine. No dietary restrictions required.
No specific food interactions have been reported with sodium tetradecyl sulfate. However, maintaining adequate hydration is recommended. Avoid excessive alcohol intake, as it may exacerbate venous insufficiency.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack of safety data, especially in the first trimester. Theoretical risk of placental transfer is low due to high molecular weight and local administration. No reported fetal anomalies.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
No data on excretion into human milk. M/P ratio unknown. Due to local administration and rapid metabolism, systemic exposure is minimal. Caution advised; consider discontinuing breastfeeding or avoiding use in lactating women.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
No specific dose adjustments recommended. Use only if clearly needed, with smallest effective volume and concentration. Physiological changes in pregnancy (increased plasma volume, altered coagulation) may affect response but no pharmacokinetic data exist.
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
Sodium tetradecyl sulfate is a sclerosing agent used for the treatment of varicose veins and telangiectasias. It works by causing endothelial damage and subsequent fibrosis of the vein. Use with caution in patients with a history of deep vein thrombosis, pulmonary embolism, or hypercoagulable states. Allergic reactions, including anaphylaxis, have been reported; a test dose is recommended. Avoid extravasation as it may cause tissue necrosis. Compression stockings should be applied post-injection to enhance efficacy and reduce complications.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
This medication is injected directly into your varicose veins to cause them to scar and close.,You may experience temporary bruising, pain, or redness at the injection site.,It is normal for the treated veins to feel hard and lumpy for a few weeks after treatment.,You will need to wear compression stockings for several days to weeks as directed by your healthcare provider.,Avoid sun exposure to the treated area until bruising resolves to reduce the risk of hyperpigmentation.,Seek immediate medical attention if you experience signs of an allergic reaction, chest pain, or difficulty breathing.,Do not discontinue prescribed blood thinners unless instructed by your doctor, as the risk of bleeding may be increased.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKRINOL vs SODIUM TETRADECYL SULFATE, answered by our medical review team.
AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. SODIUM TETRADECYL SULFATE is a Sclerosing Agent that works by Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKRINOL and SODIUM TETRADECYL SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. The standard adult dose of SODIUM TETRADECYL SULFATE is: 1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKRINOL and SODIUM TETRADECYL SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. SODIUM TETRADECYL SULFATE is classified as Category C. Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.